GTC BIOTHERAPEUTICS AND SCANCELL COLLABORATE ON SC101 ANTIBODY

GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) and Scancell Limited ("Scancell") announced that they have signed a collaboration agreement to evaluate the expression of Scancell's SC101 anti-cancer monoclonal antibody (MAb) using GTC's transgenic production platform. Their agreement contemplates that both companies will work toward the establishment of a definitive agreement for the potential clinical development of SC101.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050728005572&newsLang=en)